Home > Healthcare & Medical Devices > Growth Hormone Market

Growth Hormone Market Size By Product (Powder, Solvent), By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Medstores), Industry Analysis Report, Regional Outlook, Growth Potential, Covid-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 – 2030

  • Report ID: GMI5042
  • Base Year: 2021
  • Report Format: PDF

Industry Overview

Growth Hormone Market size surpassed USD 3 billion in 2021 and is poised to witness a robust CAGR of 6.7% between 2022 and 2030. The market will expand faster as the number of cases of growth hormone deficiency and other growth disorders rises. Increased demand for growth hormone injections in the market has resulted from increased awareness of growth hormone therapy and early diagnosis around the world.
 

Growth Hormone Market

Get more details on this report - Request Free Sample PDF
 

Furthermore, rising R&D activities in the growth hormone industry, as well as intense competition among top market players for creating innovative, cost-effective treatments, are expected to boost growth hormone market statistics. throughout the forecast timeframe.
 

COVID-19 pandemic disrupted the healthcare industry by negatively affecting the global supply chain which has affected the distribution of growth hormone medication to an extent. As growth hormone therapy is considered an essential therapy for children suffering from deficiency, also during pandemic patients showed good adherence towards therapy which did not affect the market in negatively manner. Therefore, overall demand for growth hormone in the market remain moderate.
 

Growth hormone also known as somatotropin is a 191 amino acid single-chain polypeptide hormone which is produced by the somatotropic cells of anterior pituitary gland. Major function of the growth hormone is the stimulation of development, regeneration, and growth. It is responsible for the growth of every tissue and organ and control metabolism. However, deficiency in the growth hormone might result into the decrease in skeletal muscle, low bone density, lack of energy and others.
 

Rising incidence of growth disorders will propel the product demand

Over time, there has been a gradual increase in public understanding concerning the use of synthetic growth hormone therapy. However, expanding industrial research for the causes of growth disorders, as well as an improving incidence of diagnosis, has resulted in an increase in market growth. Pediatric growth hormone deficit, idiopathic low stature, adult growth hormone deficiency, and hereditary illnesses such as Turner syndrome and Prader-Willi syndrome are just a few of these ailments. Globally, 1 in 3800 children suffers from a growth hormone deficit. Turner syndrome affects around one in every 2000 females, and Prader-Willi syndrome affects one in every 30,000 persons.
 

Despite the fact that the underlying causes of all of these illnesses are distinct, synthetic growth hormone injections are the first line of treatment. Growth hormone injections are used to treat growth hormone deficiency syndrome when the body's natural production of the hormone fails. The demand for synthetic growth hormones is predicted to rise in the market as the number of cases of these illnesses rises, propelling the industry landscape.
 

Increasing usage of synthetic growth hormone for various applications will fuel the market outlook over the forecast period

Global Growth Hormone Market, By Product

Get more details on this report - Request Free Sample PDF
 

The growth hormone market is divided into powder and solvent segments based on product. The powder segment accounted for more than USD 2 billion in 2021. The most typical method in which growth hormones are administered is in powder form. These growth hormones come in a lyophilized powder form. The lyophilized powder is then made into a suspension with various concentrations in order to generate growth hormone injectable dosages. The growth hormone injections are given to the patients subcutaneously, products of such kind are Eli Lilly and Company (Humatrope), Merck (Saizen), Pfizer (Genotropin), and Ferring Pharmaceuticals (Zomacton) are among the companies that produce growth hormones in powder form. These companies operate in various parts of the world to meet the market demand for synthetic growth hormones. Growing awareness of the treatment of growth problems, as well as increased use of synthetic growth hormones, are expected to drive market forecasts.
 

Increasing prevalence of pediatric and adult growth hormone deficiency will propel the market size

Global Growth Hormone Market, By Application

Get more details on this report - Request Free Sample PDF
 

Growth hormone deficiency, idiopathic short stature, turner syndrome, small for gestational age, prader-willi disease, and other applications make up the growth hormone market. During the forecast period, the growth hormone deficiency segment is expected to grow at a 6.9% CAGR through 2030. When the pituitary gland fails to create enough growth hormone to support the body's growth, growth hormone deficit (GHD) occurs. It causes a variety of developmental abnormalities, such as short stature, underdevelopment of body parts, and others. GHD usually affects children, although it also affects roughly 1 in 100,000 adults around the world. Until puberty, children with GHD are usually treated with synthetic growth hormones. Patients may, nevertheless, require growth hormone therapy in some instances. In some circumstances, however, people must be on growth hormone medication for the rest of their lives. The high number of patients with GHD, as well as the protracted and expensive therapy, is a major factor in this segment's high share and growth.
 

Increasing number of hospital pharmacies will offer significant market growth opportunities

The growth hormone industry based on distribution channel is segmented into online medstores, retail pharmacy, and hospital pharmacy. In 2021, the hospital pharmacy segment is expected to account for around 55% of the market, and it is expected to increase at a modest rate during the forecast period. The demand for growth hormone medicine in hospital pharmacies is increasing as the rate of diagnosis of growth problems in hospitals rises.
 

Increasing number of patients getting growth hormone therapy in North America region will accelerate the market progression

North America Growth Hormone Market, By Country

Get more details on this report - Request Free Sample PDF
 

United States growth hormone market exceeded USD 1.2 billion in 2021 and is set to register 6.7% CAGR through 2030.  The increase in sales of growth hormone injections for the treatment of various growth problems is primarily responsible for the regional expansion. The diagnosis of such growth problems has been steadily increasing, creating a demand for therapeutic solutions. Furthermore, one of the factors boosting market expansion in the region is the high disposable income of people in North American countries who have the financial means to endure costly treatment regimes.
 

Increasing number of players involved in developing novel products are augmenting the market expansion

Some of the prominent market players operating in the growth hormone market include Merck KGaA, Eli Lily And Company, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Ipsen S.A., LG Chem Ltd., Anhui Anke Biotechnology (Group) Co., Ltd, Ferring B.V., and Genetech Inc. (Roche Group). These market players have been experiencing strategic developments in order to stay competitive and gain a significant market share in the industry.
 

Some of the recent industry developments:

  • In February 2021, Pfizer and OPKO health Inc. announced that the European Medicines Agency has approved Somatrogon for the treatment of juvenile growth hormone deficient patients. Since 2014, Pfizer and OPKO are in an agreement to develop and commercialize Somatrogon for GHD treatment.
     
  • In August 2021, Ascendis Pharma received FDA approval for their SKYTROFA injectable in August 2021. This product will be released in the global market, allowing the company to generate significant revenue.
     

The growth hormone market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2030, for the following segments:

By Product

  • Powder
  • Solvent

By Application

  • Growth Hormone Deficiency
  • Idiopathic Short Stature
  • Turner Syndrome
  • Small For Gestational Age
  • Prader-Willi Syndrome
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Medstores

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
       
Authors: Sumant Ugalmugale, Rupali Swain

Frequently Asked Questions (FAQ) :

The growth hormone industry size had crossed USD 3 billion in 2021 and is expected to strike a CAGR of 6.7% between 2022 and 2030 owing to the rising number of cases related to growth hormone deficiencies and the higher awareness regarding early diagnosis.

Global demand for powder growth hormones was valued at over USD 2 billion in 2021 and will expand with the surging awareness regarding the treatment of growth problems.

The hospital pharmacy distribution channel segment held over 55% of the growth hormone industry share in 2021 and will see expansion with the rising rate of diagnosis of growth problems in these settings.

U.S. growth hormone industry size had crossed USD 1.2 billion in 2021 and will witness a 6.7% CAGR through 2030 on account of the surging sales of growth hormone injections for treating various growth problems.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Published Date: May 2022
  • Companies covered: 10
  • Tables & Figures: 196
  • Countries covered: 18
  • Pages: 180

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount